December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Tissue Plasminogen Activator (t-PA) assisted Subfoveal Hemorrhage Displacement Surgery
Author Affiliations & Notes
  • R Boada
    Ophthalmology University of Washington Seattle WA
  • R Cady
    Ophthalmology University of Washington Seattle WA
  • J Wells
    Palmetto Retina Center Columbia SC
  • W Clark
    Columbia Eye Clinic Columbia SC
  • C Goins
    Ophthalmology University of Washington Seattle WA
  • D Saperstein
    Ophthalmology University of Washington Seattle WA
  • Footnotes
    Commercial Relationships   R. Boada, None; R. Cady, None; J. Wells, None; W. Clark, None; C. Goins, None; D. Saperstein, None. Grant Identification: Research to Prevent Blindness
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3521. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R Boada, R Cady, J Wells, W Clark, C Goins, D Saperstein; Tissue Plasminogen Activator (t-PA) assisted Subfoveal Hemorrhage Displacement Surgery . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3521.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To describe subfoveal hemorrhage displacement (SFHD) to treat subretinal, subfoveal hemorrhage secondary to choroidal neovascular membranes (CNV). Methods: SFHD cases from 3 retina surgeons were reviewed retrospectively. 16 eyes were followed from 0-13 months post SFHD. Surgery involved complete vitrectomy with removal of the posterior hyaloid and subretinal injection of t-PA (6-25 micrograms/0.1 cc) into the area of subfoveal hemorrhage. Inferior detachment of the retina was performed either directly with the t-PA injection or subsequently with balanced salt solution using a 30-41 gauge cannula. A 50% gas fluid exchange was performed and approximately 40 minutes after the t-PA injection the patient was placed in an upright position and remained that way for 24 hours. Within the first post operative week, fluorescein angiography was done to visualize the etiology of the hemorrhage. Lesions that were considered treatable by photodynamic therapy (PDT) guidelines were treated accordingly. Results: 16 eyes received SFHDand were followed for 0-13 months. The subretinal hemorrhage was displaced away from the fovea in 16/16 eyes. 9/16 eyes improved by 3 or greater lines of Snellen visual acuity. 3/16 eyes maintained acuity. 3/16 eyes lost 3 or greater lines of visual acuity. 1/16 is post operative day 1 at the time of abstract submission. PDT was administered in 3/16 eyes that had predominantly classic lesions on their post operative angiograms. Complications included 2 eyes in which rebleeding occured. Conclusion: Tissue plasminogen activator assisted subfoveal hemorrhage displacement surgery may provide a superior method of managing subretinal hemorrhage as compared to observation and existing therapies.

Keywords: 308 age-related macular degeneration • 346 choroid: neovascularization • 516 photodynamic therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×